Royalty Pharma plc
RPRX
Rang in aandelen
#893
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Aandeelprijs
$60.39
Marktkapitalisatie
$26.89B
Verandering (1 dag)
-0.93%
Verandering (1 jaar)
63.17%
Land
US
Handel Royalty Pharma plc (RPRX)
Categorie
Healthcare
EPS voor Royalty Pharma plc (RPRX)
EPS per June 2026 TTM: $2.41
Volgens de laatste financiële rapporten en de aandelenkoers van Royalty Pharma plc is de huidige EPS van het bedrijf (TTM) $2.41. Eind 2024 had het bedrijf een EPS van $1.92, een daling ten opzichte van de EPS van 2023 die $2.54 bedroeg.
EPS-geschiedenis van Royalty Pharma plc van 2015 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $2.41 | 34.64% |
| 2025 | $1.79 | -6.61% |
| 2024 | $1.92 | -24.41% |
| 2023 | $2.54 | 2,492.43% |
| 2022 | $0.10 | -93.45% |
| 2021 | $1.49 | -42.47% |
| 2020 | $2.60 | -59.54% |
| 2019 | $6.42 | 182.80% |
| 2018 | $2.27 | 13.86% |
| 2017 | $1.99 | 113.83% |
| 2016 | $0.93 | -2.67% |
| 2015 | $0.96 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -78.42% |
US
|
|
| $0.02 | -99.22% |
HK
|
